Boundless Bio Inc. BOLD 深 沪
等待开盘 01-23 09:30:00 美东时间
1.27
+0.030
+2.42%
华盛通- 最 高1.31
- 今 开1.25
- 成交量 12.27万股
- 最 低 1.25
- 昨 收 1.24
- 总市值 2842.97万
- 52周最高 2.54
- 市盈率 静 --
- 换手率 0.55%
- 52周最低 1.00
- 委 比 25.46%
- 总股本 2238.56万
- 历史最高 15.24
- 量 比 0.65
- 振 幅 4.84%
- 历史最低 1.00
- 每 手 1
- 风险率 0.36%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Boundless Bio Terminates Early-Stage BBI-825 Cancer Trial: What Investors Should Know
Boundless Bio Inc. ($BOLD) announced an update on their ongoing clinical study....
01-17 00:31
Boundless Bio Q3 EPS $(0.62) Misses $(0.53) Estimate
Boundless Bio (NASDAQ:BOLD) reported quarterly losses of $(0.62) per share which missed the analyst consensus estimate of $(0.53) by 16.32 percent. This is a 16.22 percent increase over losses of $(0.74) per share from
2025-11-05 20:08
Boundless Bio To Present Preclinical Data On BBI-825 And BBI-355 Combo Targeting Oncogene-Amplified Cancers At AACR-NCI-EORTC 2025
Boundless Bio, (NASDAQ:BOLD) a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers,
2025-10-14 04:10
Boundless Bio Announces Upcoming Presentation at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company, will present a poster at the AACR-NCI-EORTC conference in Boston from October 22-26, 2025. The presentation will focus on the synergistic oral combination of BBI-825 and BBI-355, targeting oncogene amplified cancers. BBI-825 is a selective RNR inhibitor, while BBI-355 is a selective CHK1 inhibitor. Both compounds are being evaluated in the phase 1/2 POTENTIATE trial. Boundless Bio s...
2025-10-13 20:05
HC Wainwright & Co. Maintains Buy on Boundless Bio, Lowers Price Target to $4
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Boundless Bio (NASDAQ:BOLD) with a Buy and lowers the price target from $5 to $4.
2025-08-11 18:43
Boundless Bio Reports Second Quarter 2025 Financial Results and Business Highlights
Boundless Bio has announced its Q2 2025 financial results, including $127 million in cash, and highlighted progress in its oncology programs. The POTENTIATE trial's BBI-355/BBI-825 combination arm is now open for enrollment, and BBI-940 is on track for IND submission in H1 2026. The company aims to deliver proof-of-concept data for both programs within its current cash runway, supporting operations into H1 2028. R&D expenses were $12.2 million, a...
2025-08-05 11:00
Boundless Bio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company focused on extrachromosomal DNA (ecDNA) biology, announced that President and CEO Zachary Hornby will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference on June 9, 2025, in Miami, FL. The session will be live and archived on the company’s Investor Relations website. Boundless Bio is developing ecDNA-directed therapeutic candidates to address ...
2025-06-05 20:58
美股大行评级 | 再生元制药遭大摩下调评级，Aspen Insurance Hldgs(AHL)获多家机构首予“超配”评级！
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1136585934532136961.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• HC Wainwright & Co.：维持Vera Therapeutics(VERA)"买入"评级，目标价从75美元升至85美元</p> <p>• Ascendiant Capital：维持60 Degrees
2025-06-03 09:06
美股大行评级 | 拼多多遭多家大行下调评级！Redburn Atlantic首予博通"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1134767544930545665.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Guggenheim：维持AnaptysBio(ANAB)"买入"评级，目标价从54美元升至90美元</p> <p>• Canaccord Genuity：维持Bridger Aerospace Gr(BAER)"买入"评
2025-05-29 09:53
Leerink Partners Downgrades Boundless Bio to Market Perform, Lowers Price Target to $3
Leerink Partners analyst Michael Cherny downgrades Boundless Bio (NASDAQ:BOLD) from Outperform to Market Perform and lowers the price target from $15 to $3.
2025-05-28 23:53
